脳バイオマーカー市場レポート：2031年までの動向、予測、競合分析

世界の脳バイオマーカー市場の将来は、病院、研究室、外来手術センター、診断ラボの各市場における機会で有望視されています。世界の脳バイオマーカー市場は、2025年から2031年までのCAGRが7.4%で、2031年までに推定180億米ドルに達すると予想されます。この市場の主な促進要因は、神経疾患における精密な診断技術に対するニーズの高まり、精神的な問題の早期発見と管理を支援するバイオマーカーに対するニーズの高まり、個別化医療に対する需要の高まりであり、脳バイオマーカーは神経疾患患者の個別化治療計画の策定に利用できます。

• 製品タイプ別では、バイオマーカー検査キットが診断や研究において重要な役割を果たし、多様な神経疾患と関連するバイオマーカーを同定・定量する信頼性の高い効果的な技術を提供するため、予測期間中も大きなセグメントであり続けるとLucintelは予測しています。
• 最終用途別では、病院がバイオマーカーを早期疾患の特定や治療モニタリングなど様々な目的で使用するため、迅速な介入やオーダーメイドの治療レジメンが可能となり、引き続き最大セグメントとなります。
• 地域別では、北米が予測期間中最大の地域であり続けると思われます。

脳バイオマーカー市場の戦略的成長機会

脳バイオマーカー市場には、研究や技術の進歩、神経疾患の罹患率の上昇を背景に、いくつかの戦略的成長機会が生まれています。

• アルツハイマー病の早期診断：アルツハイマー病の早期診断ツールの必要性が大きな成長機会を生み出しています。バイオマーカーは早期診断に役立ち、タイムリーな介入と患者の転帰の改善を可能にします。
• 治療オプションの進歩：個別化医療へのシフトは、バイオマーカーに基づく治療への道を開いています。特定のバイオマーカー・プロファイルに基づいた治療法の開発により、より効果的で的を絞った治療が可能になり、副作用のリスクも軽減されます。
• 神経変性疾患研究への投資：パーキンソン病や多発性硬化症などの疾患に対する関心の高まりが、脳バイオマーカー研究への投資を促進しています。これらの分野で発見された新しいバイオマーカーは、これらの疾患の診断やモニタリングをより効果的に行うのに役立ちます。
• 研究協力：学界、研究機関、業界関係者間の協力関係の強化は、バイオマーカーの発見と応用を加速しています。このようなパートナーシップは、研究スケジュールの短縮や新しい診断ツールの迅速な市場投入に役立っています。
• 臨床応用の拡大：バイオマーカーを臨床に応用したいというニーズが高まっています。バイオマーカーがより広範に使用されることが検証されるにつれて、様々な神経疾患の診断や管理にバイオマーカーを応用する機会が増えると思われます。

このような機会は、脳バイオマーカー市場の継続的成長の可能性を明確にし、神経学分野における新たな発見と患者ケアの強化の道を提供します。

脳バイオマーカー市場の促進要因・課題

脳バイオマーカー製品の商業化は、利用可能な技術、社会経済および規制環境など、多くの促進要因と課題に影響されます。市場で事業を展開するためには、これらの力学を知ることが重要です。

脳バイオマーカー市場を牽引する要因は以下の通り：

• 技術の進歩：バイオマーカー検出とその分析の原理、方法、手段の絶え間ない技術改良が市場の成長を確実なものにしています。新たな識別子や診断想像力の開発、ゲノムおよびプロテオミクス技術は、診断における感度と特異性を向上させます。
• 研究資金の増加：神経科学と神経疾患の研究に割り当てられる投資の増加が脳バイオマーカーの成長を促進しています。臨床試験の資金調達は通常多額であるため、効果的な意思決定につながる検証プロセスが助成され、促進されます。
• 神経疾患の発生率の上昇：アルツハイマー病やパーキンソン病の新規患者は増加傾向にあり、効果的な診断ソリューションが求められています。このような場合、バイオマーカーは臨床的な検出や状態のモニタリングに役立ちます。
• バイオマーカーに基づく検査の需要増加：個別化医療の普及により、バイオマーカーに基づく診断が求められるようになりました。臨床診療としての腫瘍学は、特定の患者のニーズに合わせた治療アプローチが臨床転帰を改善するため、バイオマーカーから恩恵を受けます。
• 助成金申請の共同支援：学術界、産業界、臨床界のパートナーとの効果的な協力関係による並行発明が、脳バイオマーカー開発の努力を支えています。このような協力関係がリソースの共有を促進し、進歩のスピードアップに役立っています。

脳バイオマーカー市場における課題は以下の通り：

• 規制上の障壁：バイオマーカーに基づく診断機器の承認取得には時間とコストがかかります。承認プロセスに時間がかかると、必要とする患者への新しい診断ツールの提供が遅れる可能性があります。
• 財政的障壁：脳バイオマーカーの開発と検証に伴う高いコストは、特に資金力の乏しい中小企業にとって課題となります。このため、進歩が遅れ、革新的なソリューションへのアクセスが制限される可能性があります。
• 市場競争：脳バイオマーカー市場に参入する企業が増加し、競争が激化しています。企業は競争力を維持し、市場シェアを獲得するために、製品やサービスを差別化しなければなりません。

市場促進要因・課題を克服することが、脳バイオマーカー分野で成功するための鍵となります。

新興諸国はそれぞれ、神経疾患の診断精度の向上と治療介入に焦点を当て、脳バイオマーカーの開発に大きく貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の脳バイオマーカー市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 世界の脳バイオマーカー市場の動向（2019～2024年）と予測（2025～2031年）
• 製品タイプ別：世界の脳バイオマーカー市場
  • バイオマーカー検査キット
  • バイオマーカー分析装置
• 疾患適応症別：世界の脳バイオマーカー市場
  • 脳卒中
  • 筋萎縮性側索硬化症と筋萎縮性側索硬化症
  • アルツハイマー病およびその他の認知症
  • パーキンソン病
  • ハンチントン病
• 用途別：世界の脳バイオマーカー市場
  • 診断
  • 医薬品の発見と開発
  • その他
• 最終用途別：世界の脳バイオマーカー市場
  • 病院
  • 調査室
  • 外来手術センター
  • 診断検査室
  • その他

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別：世界の脳バイオマーカー市場
• 北米の脳バイオマーカー市場
• 欧州の脳バイオマーカー市場
• アジア太平洋の脳バイオマーカー市場
• その他地域の脳バイオマーカー市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 製品タイプ別の世界の脳バイオマーカー市場の成長機会
  • 疾患適応症別の世界の脳バイオマーカー市場の成長機会
  • 用途別の世界の脳バイオマーカー市場の成長機会
  • 最終用途別の世界の脳バイオマーカー市場の成長機会
  • 地域別の世界の脳バイオマーカー市場の成長機会
• 世界の脳バイオマーカー市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の脳バイオマーカー市場の能力拡大
  • 世界の脳バイオマーカー市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

The future of the global brain biomarker market looks promising with opportunities in the hospital, research laboratory, ambulatory surgical center, and diagnostic laboratory markets. The global brain biomarker market is expected to reach an estimated $18 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the increased need for precise diagnostic techniques in neurological diseases, the rising need for biomarkers to aid in the early identification and management of mental health issues, and the growing demand for personalized medicine, brain biomarkers can be used to develop personalized treatment plans for patients with neurological disorders.

• Lucintel forecasts that, within the product type category, biomarker test kit will remain the larger segment over the forecast period due to their critical role in diagnostics and research, offering a reliable and effective technique to identify and quantify biomarkers linked with diverse neurological disorders.
• Within the end use category, hospitals will remain the largest segment due to hospitals use biomarkers for a variety of objectives, including early illness identification and treatment monitoring, which allows for prompt interventions and tailored care regimens.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Brain Biomarker Market

The brain biomarker market is undergoing significant transformation driven by technological advancements, research funding, and the growing emphasis on personalized medicine. These trends are reshaping the way neurological disorders are diagnosed, monitored, and treated.

• AI and Machine Learning Integration: Artificial intelligence (AI) and machine learning are revolutionizing the brain biomarker field by analyzing complex datasets more efficiently. These technologies enhance the discovery of new biomarkers and improve the predictive accuracy of existing ones, simplifying diagnosis and treatment plans.
• Personalized Medicine Approach: Personalized medicine is gaining traction in the brain biomarker market, with treatments increasingly tailored to individual biomarker profiles. By leveraging genetic profiling and biomarker analysis, healthcare providers can customize treatments to improve patient outcomes and minimize adverse effects.
• Increased Investment in Research: Growing funding from both public and private sectors is fueling research into neurological diseases, leading to the discovery of new biomarkers. This investment is critical for early detection, more accurate diagnosis, and more effective treatments.
• Collaboration Between Sectors: Enhanced collaboration between academia, industry, and healthcare organizations is accelerating biomarker development. These partnerships facilitate the transfer of knowledge and resources, leading to faster development and implementation of biomarker-based diagnostics and treatments.
• Regulatory Advancements: Regulatory landscapes are evolving, particularly in Western countries, where there is a growing push to incorporate biomarkers into clinical applications. Relaxation of market access barriers is helping to expedite the use of biomarkers in clinical practice.

These trends are significantly impacting the brain biomarker market, improving both the speed and accuracy of diagnosis and leading to more effective therapeutic interventions for neurological diseases.

Recent Developments in the Brain Biomarker Market

Recent advancements in the brain biomarker market are a result of ongoing technological progress and increased research efforts, particularly in the areas of biomarker discovery, validation, and clinical application.

• FDA Approvals for Novel Biomarkers: Recent FDA approvals of blood-based biomarkers for Alzheimer's disease have opened up new avenues for early detection and treatment. These innovations offer the potential for earlier interventions and more targeted therapeutic strategies.
• AI-Based Biomarker Discovery: The integration of AI in the biomarker discovery process is transforming how large datasets, including genetic and neuroimaging data, are analyzed. AI-driven approaches can identify novel biomarkers with higher predictive potential, enabling earlier diagnosis and better treatment outcomes.
• Collaborative Research Ventures: The convergence of academic institutions, biotech companies, and healthcare providers is accelerating the pace of biomarker development. These partnerships are focused on translating biologically validated biomarkers into clinical practice, bringing innovations to market faster.
• Focus on Proteomics and Genomics: Proteomic and genomic technologies are playing a central role in the search for brain biomarkers. These techniques are uncovering potential biomarkers that can be used for the early detection and monitoring of neurodegenerative diseases.
• Improved Imaging Modalities: Advances in imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), are enhancing the sensitivity, specificity, and quantification of cerebral biomarkers. These imaging advancements are crucial for better understanding and diagnosing brain diseases.

These recent developments are propelling the brain biomarker market forward, with improvements in analytical capabilities and clinical applications leading to better diagnostic and therapeutic strategies.

Strategic Growth Opportunities for Brain Biomarker Market

Several strategic growth opportunities are emerging within the brain biomarker market, driven by advances in research, technology, and the rising incidence of neurological disorders.

• Alzheimer's Disease Early Diagnosis: The need for early diagnostic tools for Alzheimer's disease is creating significant growth opportunities. Biomarkers can aid in early diagnosis, allowing for timely intervention and improved patient outcomes.
• Advancing Treatment Options: The shift toward personalized medicine is paving the way for biomarker-based therapies. Developing treatments based on specific biomarker profiles will enable more effective and targeted therapies, reducing the risk of side effects.
• Investments in Neurodegenerative Disease Research: Growing concerns about diseases like Parkinson's and multiple sclerosis are driving investments in brain biomarker research. New biomarkers discovered in these areas will aid in diagnosing and monitoring these conditions more effectively.
• Research Collaborations: Increasing collaboration between academia, research organizations, and industry players is accelerating biomarker discovery and application. These partnerships are helping to shorten research timelines and bring new diagnostic tools to market more quickly.
• Expanding Clinical Applications: There is a growing demand for the integration of biomarkers into clinical practice. As biomarkers are validated for broader use, there will be more opportunities to apply them in the diagnosis and management of various neurological diseases.

These opportunities underscore the potential for continued growth in the brain biomarker market, offering avenues for new discoveries and enhanced patient care in the field of neurology.

Brain Biomarker Market Driver and Challenges

The commercialization of brain biomarker products is influenced by a number of drivers and challenges such as available technology, and socio-economic and regulatory environment. It is important to know these dynamics in order to operate in the market.

The factors responsible for driving the brain biomarker market include:

• Technological Advancements: The constant technological improvement of principles, methods, and means of biomarker detection and their analysis is ensuring market growth. Development of new identifiers and diagnostic imagination, genomic and proteomic technologies improves sensitivity and specificity in diagnosis.
• Increased Research Funding: The growth in the investment allocated for neuroscience and neurological disorder studies is promoting the growth of brain biomarkers. Financing of clinical trials is usually heavy, and this subsidizes and hastens the process of verification leading to effective decision-making.
• Rising Incidence of Neurological Disorders: New cases of Alzheimer's and Parkinson's diseases are on the rise which in turn pushes for effective diagnostic solutions. Biomarkers, in such cases, help in clinical detection as well as monitoring of the condition.
• Increasing Demand For Biomarker Based Tests: The increase in the adoption of personalized medicine has seen biomarker based diagnostics become sought after. Oncology as a clinical practice benefits from biomarkers since treatment approaches are catered to the needs of specific patients improving clinical outcomes.
• Jointly Helping To Apply For The Grant: Parallel inventions through effective collaborations with academic, industrial, and clinical partners are supporting brain biomarkers developmental efforts. These cooperative relationships foster resource sharing which helps in speeding up progress.

Challenges in the brain biomarker market are:

• Regulatory Barriers: Obtaining regulatory approval for biomarker-based diagnostic devices can be time-consuming and costly. Slow approval processes can delay the availability of new diagnostic tools to patients in need.
• Financial Barriers: The high costs associated with the development and validation of brain biomarkers pose a challenge, particularly for smaller companies with limited financial resources. This can slow down progress and limit access to innovative solutions.
• Market Competition: The growing number of companies entering the brain biomarker market is intensifying competition. Companies must differentiate their products and services to maintain a competitive edge and capture market share.

Navigating these challenges while capitalizing on market drivers will be key to the success of companies in the brain biomarker space.

List of Brain Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies brain biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the brain biomarker companies profiled in this report include-

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

Brain Biomarker by Segment

The study includes a forecast for the global brain biomarker market by product type, disease indication, application, end use, and region.

Brain Biomarker Market by Product Type [Analysis by Value from 2019 to 2031]:

• Biomarker Test Kits
• Biomarker Analyzers

Brain Biomarker Market by Disease Indication [Analysis by Value from 2019 to 2031]:

• Stroke
• MND & ALS
• Alzheimer's Disease & Other Dementias
• Parkinson's Disease
• Huntington's Disease

Brain Biomarker Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnosis
• Drug Discovery and Development
• Others

Brain Biomarker Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Research Laboratories
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others

Brain Biomarker Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Brain Biomarker Market

The brain biomarker market is growing globally, with key contributions from countries like the United States, China, Germany, India, and Japan. Each of these countries is making strides in the development of brain biomarkers and their clinical applications.

• United States: The U.S. is leading in brain biomarker research and development, particularly in the area of Alzheimer's disease. Recent FDA approvals for blood-based amyloid-beta biomarkers have paved the way for new diagnostic methods. The use of AI in biomarker analysis is also growing, enhancing diagnostic accuracy and speed.
• China: China is investing heavily in brain biomarker research, particularly for neurodegenerative diseases. Collaborations with international institutions are helping to validate biomarkers, and AI integration is improving data analysis capabilities. Rising mental health awareness is driving demand for more biomarker studies.
• Germany: Germany is at the forefront of brain biomarker development, with advancements in imaging technologies and a strong emphasis on clinical implementation. The country is also promoting deeper collaboration between industries and universities to drive innovation.
• India: India's brain biomarker market is expanding due to increased research activities in neurology and psychiatry. Researchers are focusing on low-cost biomarker discovery, which makes the technology more accessible to the local population. The increasing prevalence of neurological diseases is further driving demand.
• Japan: Japan is a leader in integrating AI technologies into brain biomarker research. The country is also advancing the use of biomarkers in clinical trials for neuro-stimulating drugs, improving patient outcomes and treatment efficacy.

Each of these countries is making significant contributions to the development of brain biomarkers, with a focus on improving diagnostic accuracy and therapeutic interventions for neurological diseases.

Features of the Global Brain Biomarker Market

Market Size Estimates: Brain biomarker market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Brain biomarker market size by various segments, such as by product type, disease indication, application, end use, and region in terms of value ($B).

Regional Analysis: Brain biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, disease indication, application, end use, and regions for the brain biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the brain biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the brain biomarker market by product type (biomarker test kits and biomarker analyzers), disease indication (stroke, MND & ALS, Alzheimer's disease & other dementias, Parkinson's disease, and Huntington's disease), application (diagnosis, drug discovery and development, and others), end use (hospitals, research laboratories, ambulatory surgical centers, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Brain Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Brain Biomarker Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Brain Biomarker Market by Product Type
  • 3.3.1: Biomarker Test Kits
  • 3.3.2: Biomarker Analyzers
• 3.4: Global Brain Biomarker Market by Disease Indication
  • 3.4.1: Stroke
  • 3.4.2: MND & ALS
  • 3.4.3: Alzheimer's Disease & Other Dementias
  • 3.4.4: Parkinson's Disease
  • 3.4.5: Huntington's Disease
• 3.5: Global Brain Biomarker Market by Application
  • 3.5.1: Diagnosis
  • 3.5.2: Drug Discovery and Development
  • 3.5.3: Others
• 3.6: Global Brain Biomarker Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Research Laboratories
  • 3.6.3: Ambulatory Surgical Centers
  • 3.6.4: Diagnostic Laboratories
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Brain Biomarker Market by Region
• 4.2: North American Brain Biomarker Market
  • 4.2.1: North American Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.2.2: North American Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.3: European Brain Biomarker Market
  • 4.3.1: European Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.3.2: European Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.4: APAC Brain Biomarker Market
  • 4.4.1: APAC Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.4.2: APAC Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.5: ROW Brain Biomarker Market
  • 4.5.1: ROW Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.5.2: ROW Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Brain Biomarker Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Brain Biomarker Market by Disease Indication
  • 6.1.3: Growth Opportunities for the Global Brain Biomarker Market by Application
  • 6.1.4: Growth Opportunities for the Global Brain Biomarker Market by End Use
  • 6.1.5: Growth Opportunities for the Global Brain Biomarker Market by Region
• 6.2: Emerging Trends in the Global Brain Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Brain Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Brain Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Siemens Healthineers
• 7.2: Electrical Geodesics
• 7.3: Lifesign
• 7.4: Advanced Brain Monitoring
• 7.5: BrainScope
• 7.6: GE Healthcare
• 7.7: Johnson & Johnson
• 7.8: Natus Medical
• 7.9: F. Hoffmann-La Roche
• 7.10: Qiagen